First-time generic drug approvals, May 2009
Generic drugs approved by FDA (through May 2009) including drospirenone and ethinyl estradiol, levalbuterol, and topiramate
Drospirenone and ethinyl estradiol tablets, 3 mg/0.02 mg (equiv to Yaz tablets)
TEVA
Carbamazepine extended-release tablets, 100, 200, and 400 mg (equiv to Tegretol XR tablets)
TARO
Levalbuterol inhalation solution, 1.25 mg/0.5 mL (equiv to Xopenex inhalation solution)
DEY
Topiramate tablets, 25, 50, 100, and 200 mg (equiv to Topamax tablets)
VARIOUS MANUFACTURERS, INCLUDING TEVA, ZYDUS, UNICHEM, AUROBINDO, INVAGEN, SUN, BARR, ROXANE, GLENMARK, COBALT, APOTEX, MYLAN, CIPLA, PAR, RANBAXY, AND TORRENT
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
